172 related articles for article (PubMed ID: 37884663)
21. Association of CDH1 and TERT Single-Nucleotide Polymorphisms with Susceptibility to Familial Breast Cancer Risk.
Bagherpour M; Gharibzad K; Rassi H
Monoclon Antib Immunodiagn Immunother; 2018 Dec; 37(6):239-244. PubMed ID: 30543312
[TBL] [Abstract][Full Text] [Related]
22. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in human telomerase reverse transcriptase (hTERT) gene, gene- gene and gene-smoking interaction with susceptibility to gastric cancer in Chinese Han population.
Zhang J; Ju H; Gao JR; Jiao XL; Lu Y
Oncotarget; 2017 Mar; 8(12):20235-20243. PubMed ID: 28423629
[TBL] [Abstract][Full Text] [Related]
24. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
25. Genetic biomarkers for hepatocellular cancer risk in a caucasian population.
De Mattia E; Cecchin E; Polesel J; Bignucolo A; Roncato R; Lupo F; Crovatto M; Buonadonna A; Tiribelli C; Toffoli G
World J Gastroenterol; 2017 Sep; 23(36):6674-6684. PubMed ID: 29085212
[TBL] [Abstract][Full Text] [Related]
26. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in human telomerase reverse transcriptase (hTERT) gene polymorphisms do not associated with breast cancer in patients in a turkish population: hospital-based case-control study.
Aydin M; Sümbül AT; Camuz Hilaloğullari G; Bayram S
Cell Mol Biol (Noisy-le-grand); 2018 Feb; 64(3):108-115. PubMed ID: 29506639
[TBL] [Abstract][Full Text] [Related]
28. The
Hong T; Luo M; Liu Q
Genet Test Mol Biomarkers; 2020 Apr; 24(4):181-187. PubMed ID: 32202925
[No Abstract] [Full Text] [Related]
29. Association between the rs2736100 polymorphisms of telomerase reverse transcriptase gene and digestive cancers: A meta-analysis.
Song H; Han M; Li K; Zhao Y; Xu C; Lei X
J Cancer Res Ther; 2021 Nov; 17(5):1202-1208. PubMed ID: 34850768
[TBL] [Abstract][Full Text] [Related]
30. Leucocyte telomere length, genetic variants at the
Bao Y; Prescott J; Yuan C; Zhang M; Kraft P; Babic A; Morales-Oyarvide V; Qian ZR; Buring JE; Cochrane BB; Gaziano JM; Giovannucci EL; Manson JE; Ng K; Ogino S; Rohan TE; Sesso HD; Stampfer MJ; Fuchs CS; De Vivo I; Amundadottir LT; Wolpin BM
Gut; 2017 Jun; 66(6):1116-1122. PubMed ID: 27797938
[TBL] [Abstract][Full Text] [Related]
31. Genetic Polymorphism of Epidermal Growth Factor Gene as a Predictor of Hepatocellular Carcinoma in Hepatitis C Cirrhotic Patients.
Baghdadi I; Abu Ella K; El Shaaraway A; Elshayeb E; El-Rebey HS; El Hoseeny M; Naguib M; Nada A
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2047-2053. PubMed ID: 32711431
[TBL] [Abstract][Full Text] [Related]
32. The telomerase gene polymorphisms, but not telomere length, increase susceptibility to primary glomerulonephritis/end stage renal diseases in females.
Sun Q; Liu J; Cheng G; Dai M; Liu J; Qi Z; Zhao J; Li W; Kong F; Liu G; Björkholm M; Xu D
J Transl Med; 2020 May; 18(1):184. PubMed ID: 32366311
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation in
Buch S; Innes H; Lutz PL; Nischalke HD; Marquardt JU; Fischer J; Weiss KH; Rosendahl J; Marot A; Krawczyk M; Casper M; Lammert F; Eyer F; Vogel A; Marhenke S; von Felden J; Sharma R; Atkinson SR; McQuillin A; Nattermann J; Schafmayer C; Franke A; Strassburg C; Rietschel M; Altmann H; Sulk S; Thangapandi VR; Brosch M; Lackner C; Stauber RE; Canbay A; Link A; Reiberger T; Mandorfer M; Semmler G; Scheiner B; Datz C; Romeo S; Ginanni Corradini S; Irving WL; Morling JR; Guha IN; Barnes E; Ansari MA; Quistrebert J; Valenti L; Müller SA; Morgan MY; Dufour JF; Trebicka J; Berg T; Deltenre P; Mueller S; Hampe J; Stickel F
Gut; 2023 Feb; 72(2):381-391. PubMed ID: 35788059
[TBL] [Abstract][Full Text] [Related]
34. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
Zayed SA; Zahran NM; Khorshied MM; Abdel-Aziz AO; Mahmoud O; Morsy SA; Shousha HI; Elbaz TM; Nabeel MM; Harb ARK
J Med Virol; 2019 Aug; 91(8):1537-1544. PubMed ID: 30945308
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
36. The identification of two regulatory ESCC susceptibility genetic variants in the TERT-CLPTM1L loci.
Zhou L; Fu G; Wei J; Shi J; Pan W; Ren Y; Xiong X; Xia J; Shen Y; Li H; Yang M
Oncotarget; 2016 Feb; 7(5):5495-506. PubMed ID: 26716642
[TBL] [Abstract][Full Text] [Related]
37. Study of Toll-like Receptor 3 Gene Polymorphism as a Novel Risk Factor for HCV-related Hepatocellular Carcinoma in Egypt.
El-Sharawy S; Negm OE; Abd-Elsalam S; El-Sorogy HA; Shehata MAH
Curr Cancer Drug Targets; 2020; 20(5):382-389. PubMed ID: 32189594
[TBL] [Abstract][Full Text] [Related]
38. Genetic variants of APEX1 p.Asp148Glu and XRCC1 p.Gln399Arg with the susceptibility of hepatocellular carcinoma.
Saad AM; Abdel-Megied AES; Elbaz RA; Hassab El-Nabi SE; Elshazli RM
J Med Virol; 2021 Nov; 93(11):6278-6291. PubMed ID: 34289138
[TBL] [Abstract][Full Text] [Related]
39. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
40. Genetic variants in TERT-CLPTM1L genetic region associated with several types of cancer: a meta-analysis.
Li C; Yin Z; Wu W; Li X; Zhou B
Gene; 2013 Sep; 526(2):390-9. PubMed ID: 23707794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
